SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
VaccinesGene Therapeutics & RNAi

PUBLISHER: Meticulous Research | PRODUCT CODE: 2138415

Cover Image

PUBLISHER: Meticulous Research | PRODUCT CODE: 2138415

mRNA Vaccines Market Size, Share by Type, Technology, Indication, Age Group, Distribution Channel, and Geography - Global Forecast to 2036

PUBLISHED:
PAGES: 286 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4175
PDF & Excel (Multi User License)
USD 5875
PDF & Excel (Global Site License)
USD 7875

Add to Cart

Description

Table of Contents

List of Tables

The global mRNA Vaccines Market was valued at USD 6,446.2 million in 2025 and is estimated to reach USD 4,546.1 million in 2026. The market is projected to reach USD 11,723.5 million by 2036, registering a CAGR of 9.9% during the forecast period (2026-2036). This report provides a comprehensive assessment of the rapidly evolving mRNA vaccines market by examining prophylactic and therapeutic vaccines, conventional and self-amplifying mRNA technologies, respiratory vaccines, individualized cancer vaccines, manufacturing partnerships, competitive developments, and future growth opportunities across infectious disease prevention and oncology.

mRNA vaccines use messenger RNA delivered into cells through lipid nanoparticles or other delivery systems to instruct the body to produce an antigen that trains the immune system to prevent infection or attack a tumor. The market covers prophylactic vaccines against COVID-19, respiratory syncytial virus, seasonal and pandemic influenza, combination respiratory diseases, cytomegalovirus and other latent viruses, and other infectious diseases, as well as therapeutic cancer vaccines. It includes conventional non-replicating mRNA, self-amplifying mRNA, and circular and next-generation RNA technologies distributed through pharmacies, hospitals, clinics, public health programs, and oncology centers.

The growth of this market is mainly driven by the speed and adaptability of the mRNA platform, the expansion of approved mRNA vaccines beyond COVID-19 into RSV, seasonal influenza, and combination respiratory vaccines, the advancement of individualized mRNA cancer vaccines, and international partnerships backed by regional manufacturing. In addition, individualized neoantigen cancer vaccines, combination respiratory vaccines, self-amplifying mRNA, improved thermostability, lower-dose formulations, and the expansion of mRNA manufacturing capabilities in emerging markets are expected to create significant opportunities for market participants.

The market is transitioning from a pandemic-driven revenue model toward a broader commercial platform. The global mRNA Vaccines Market is projected to reach USD 11,723.5 million by 2036 after declining from USD 8,855.8 million in 2024 to an estimated USD 4,546.1 million in 2026 as COVID-19 vaccine demand contracted. Growth from 2027 onward is expected to be driven by RSV, influenza, combination respiratory vaccines, and therapeutic cancer vaccines. This report evaluates the impact of annual vaccination recommendations, reimbursement, vaccine hesitancy, manufacturing capacity, clinical outcomes, intellectual property, and government procurement on the market's future development.

This report delivers an in-depth analysis of the market by evaluating vaccine types, RNA technologies, indications, age groups, distribution channels, clinical adoption trends, regulatory developments, manufacturing partnerships, supply-chain strategies, and competitive activities shaping industry growth. It assesses how next-generation formulations, refrigerator-stable products, lower-dose vaccines, self-amplifying RNA, individualized neoantigen design, lipid nanoparticle delivery, and regional technology transfer are improving scalability, convenience, and commercial potential. The study also provides strategic market forecasts, segment-level insights, and regional analysis to support informed business, investment, product development, and market-entry decisions.

Market Dynamics

The speed and adaptability of the mRNA platform remain among the primary drivers of the mRNA Vaccines Market. mRNA vaccines are produced through cell-free in vitro transcription, and manufacturing, purification, and lipid nanoparticle formulation can be adapted to new antigens without rebuilding an entirely different production system. This flexibility supports rapid response to emerging pathogens, annual variant updates, seasonal influenza development, pandemic preparedness, and the design of patient-specific cancer vaccines. The ability to encode multiple antigens within a single construct also supports the development of combination respiratory vaccines.

The expansion of mRNA vaccines beyond COVID-19 is further accelerating market transformation. RSV vaccines, seasonal influenza candidates, combination influenza and COVID-19 products, and vaccines targeting latent viruses are broadening the commercial product base. The approval of products such as mRESVIA, mNEXSPIKE, mFLUSIVA, and mCOMBRIAX demonstrates the expanding application of mRNA technology in adult respiratory vaccination. Portfolio diversification is reducing dependence on COVID-19 demand and enabling developers to compete across the full seasonal vaccination visit.

The advancement of individualized mRNA cancer vaccines is creating the largest long-term opportunity. In these therapies, a patient's tumor is sequenced, immunogenic neoantigens are predicted, and a customized mRNA construct is manufactured for administration with a checkpoint inhibitor. The Phase 3 INTerpath-001 trial of intismeran autogene met its primary endpoint in patients with resected melanoma, strengthening the potential for regulatory filings and future expansion into lung, bladder, renal, and other solid tumors. Therapeutic cancer vaccines can also generate oncology-like revenue that is less dependent on seasonal respiratory vaccination and public health recommendations.

Self-amplifying mRNA and next-generation formulations are supporting additional growth opportunities. Self-amplifying mRNA encodes both an antigen and a replicase that copies the RNA inside cells, enabling lower doses and reducing raw material requirements. Products using this technology can improve manufacturing efficiency and expand pandemic output from existing facilities. Refrigerator-stable presentations and lower-dose formulations are also simplifying distribution through pharmacies and physician offices, reducing dependence on deep-frozen storage and improving access in markets with less-developed cold-chain infrastructure.

International partnerships and regional manufacturing are reshaping market development. Japan, China, and India have authorized domestically developed mRNA vaccines, while the WHO technology transfer program and EU FAB network are expanding regional preparedness and manufacturing capacity. Partnerships between vaccine developers, governments, contract manufacturers, and technology-transfer organizations are supporting local production, supply security, and access to mRNA vaccines in emerging markets.

Despite favorable long-term opportunities, the sharp post-pandemic decline in COVID-19 vaccine demand remains the market's most important restraint. National programs have shifted from whole-population purchases toward booster campaigns for older and higher-risk groups. Uptake has declined in several markets as vaccination moved to routine programs with co-payments, and recommendations differ across countries. Narrower eligibility criteria and individual-based decision-making are making annual demand more difficult to forecast.

Reversal of public funding and manufacturing overcapacity represent additional challenges. Government support for pandemic mRNA programs has been reduced in some markets, while capacity built for billions of doses is now underused. Variant-specific products have limited carryover between seasons, so lower uptake can result in inventory losses and write-downs. The commercial volatility of the COVID-19 market has affected manufacturers, raw material suppliers, and specialized mRNA production partners.

Safety perceptions, vaccine hesitancy, clinical setbacks, and intellectual property disputes may also limit adoption. Rare myocarditis and pericarditis, reactogenicity, misinformation, and concerns regarding vaccine durability can influence acceptance. Clinical setbacks in CMV, influenza, and cancer programs can delay product launches, while overlapping patents covering nucleoside modifications, lipid nanoparticles, and sequence design can increase costs and create uncertainty for developers and new entrants.

The market nevertheless presents substantial opportunities through individualized neoantigen vaccines, combination respiratory vaccines, self-amplifying mRNA, thermostable formulations, regional manufacturing, pandemic preparedness, and expansion in Asia-Pacific and the Middle East & Africa. Companies that can demonstrate durable clinical protection, convenient storage, cost-efficient manufacturing, strong intellectual property, and reliable distribution are expected to be well positioned to benefit from the market's post-pandemic diversification.

Segment Analysis

The report provides detailed market analysis across type, technology, indication, age group, distribution channel, and geography, enabling stakeholders to identify high-growth opportunities and evolving trends in respiratory immunization, cancer vaccines, next-generation RNA, vaccine manufacturing, and public health delivery.

Based on type, the market is segmented into Prophylactic Vaccines and Therapeutic Vaccines. Prophylactic Vaccines are expected to account for the entire market in 2026 because all mRNA vaccines approved as of September 2026 are prophylactic vaccines against infectious diseases. This segment is projected to reach USD 8,113.5 million by 2036, at a CAGR of 6.0%, as growth in RSV, influenza, and combination respiratory vaccines offsets the decline in COVID-19 vaccines. However, Therapeutic Vaccines are projected to register the higher growth rate during the forecast period and reach USD 3,610.0 million by 2036, driven by the expected approval of individualized neoantigen vaccines and their expansion into additional solid tumors.

Based on technology, the market is segmented into Conventional Non-Replicating mRNA, Self-Amplifying mRNA, and Circular & Next-Generation RNA. Conventional Non-Replicating mRNA is expected to account for the largest share of 99.2% of the market in 2026, reflecting the current commercial base of COVID-19, RSV, influenza, combination, and leading oncology candidates. However, Self-Amplifying mRNA is projected to register the highest CAGR of 34.2% during the forecast period, driven by lower-dose products, reduced raw material requirements, improved manufacturing efficiency, and expanding pandemic and infectious disease programs.

Based on indication, the market is segmented into COVID-19, RSV, Influenza, Combination Respiratory Vaccines, CMV & Latent Viruses, Oncology, and Other Infectious Diseases. COVID-19 is expected to account for the largest share of 93.6% of the market in 2026, reflecting annual variant-adapted vaccination among older and high-risk adults, but the segment is projected to decline at a CAGR of -7.8%. Oncology is projected to become the largest indication by 2036, driven by individualized neoantigen vaccines and therapeutic cancer vaccine development. Among indications with sales in 2026, Combination Respiratory Vaccines are projected to register the highest CAGR of 57.3%, followed by Influenza at 50.3%.

Based on age group, the market is segmented into Adults Aged 65+ & High-Risk Adults, Adults Aged 18-64, and Pediatric. Adults Aged 65+ & High-Risk Adults are expected to account for the largest share of 79.0% of the market in 2026, reflecting the concentration of COVID-19, RSV, and influenza recommendations on older adults and people with underlying conditions. However, Adults Aged 18-64 are projected to register the highest CAGR of 17.0% during the forecast period, driven by therapeutic cancer vaccines for patients under 65, the approval of influenza vaccines for younger adult groups, and the extension of RSV and combination vaccines to broader adult populations.

Based on distribution channel, the market is segmented into Pharmacies & Retail Clinics, Hospitals & Clinics, Government & Public Health Programs, and Oncology Centers. Pharmacies & Retail Clinics are expected to account for the largest share of 43.5% of the market in 2026, reflecting the central role of retail pharmacies in adult seasonal vaccination, particularly in the U.S. Government & Public Health Programs are projected to register the highest CAGR of 8.2% among channels with sales in 2026, driven by national partnerships and European joint procurement. Oncology Centers are projected to reach USD 3,324.6 million by 2036 as therapeutic cancer vaccines are introduced and integrated into oncology treatment pathways.

Regional Analysis

The report provides comprehensive market analysis across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Regional evaluations consider vaccination recommendations, public procurement, reimbursement, adult immunization, vaccine manufacturing, technology transfer, clinical development, cold-chain infrastructure, regulatory approvals, and investments influencing market growth.

North America is expected to account for the largest share of 41.7% of the global mRNA Vaccines Market in 2026. The region's leadership is attributed to the size and pricing of the U.S. market, the presence of Moderna and Pfizer and their manufacturing networks, extensive retail pharmacy vaccination, established healthcare infrastructure, and the U.S. focus of the first individualized cancer vaccine launches. The U.S. is expected to account for 93.0% of the regional market and 38.8% of the global market in 2026. North America is projected to grow at a CAGR of 10.2% despite narrower COVID-19 recommendations and a reversal of some federal funding.

Europe is expected to account for the second-largest share of 34.8% of the market in 2026. The region is supported by BioNTech's home market, European Commission joint procurement, the early authorization of mCOMBRIAX, and all-adult mRESVIA authorization in the European Union. Germany is expected to account for the largest share of the regional market, at 20.1%, while France and the U.K. are projected to grow rapidly, supported by strategic manufacturing partnerships and facilities such as Moderna's Harwell site. European joint procurement and regional preparedness initiatives are expected to continue supporting demand.

Asia-Pacific is projected to register the highest CAGR of 12.3% during the forecast period. Japan, China, and India have authorized domestically developed mRNA vaccines, while Australia, South Korea, and other markets are expanding domestic manufacturing, clinical development, and pandemic preparedness. Japan is expected to account for the largest share of the regional market, at 43.9%, in 2026, while China and India are projected to register very high growth rates from relatively small bases. Domestic RSV, shingles, mpox, therapeutic HPV, combination respiratory, and cancer vaccine programs are expected to create additional opportunities.

Latin America is expected to account for a share of 6.2% of the market in 2026 and to grow at a CAGR of 6.3%. Brazil is expected to account for 46.7% of the regional market, supported by Moderna's agreements in Brazil and Mexico, regional manufacturing under technology-transfer programs, and expanding adult vaccination. However, public procurement and Pan American Health Organization pricing keep vaccine prices below North American and European levels, affecting revenue potential.

The Middle East & Africa is expected to account for a share of 3.2% of the market in 2026 and to grow at a CAGR of 9.9%. Growth is driven by vaccination programs in Saudi Arabia, the UAE, and Israel, regional pandemic preparedness, and mRNA manufacturing initiatives in Africa. BioNTech's Kigali site in Rwanda and WHO technology-transfer partners are supporting local production capabilities. South Africa and the UAE are projected to be among the fastest-growing country markets.

Competitive Landscape

The report presents a comprehensive evaluation of the competitive environment by examining the strategic positioning of leading market participants, their prophylactic and therapeutic vaccine portfolios, RNA technologies, clinical pipelines, lipid nanoparticle delivery systems, manufacturing networks, regulatory approvals, public procurement agreements, partnerships, acquisitions, intellectual property, geographic expansion initiatives, research and development investments, and recent business developments.

Competitive benchmarking enables stakeholders to evaluate companies based on clinical efficacy, durability of protection, breadth of approved indications, platform adaptability, manufacturing scale, cold-chain requirements, dose efficiency, safety profile, regulatory progress, intellectual property, distribution reach, and pricing. The study also analyzes how market participants are responding to the decline in COVID-19 demand, the shift toward older and high-risk adult vaccination, the growth of combination respiratory vaccines, self-amplifying mRNA, individualized cancer vaccines, and regional manufacturing requirements.

The global mRNA Vaccines Market has a layered competitive structure involving the originators of the first approved mRNA vaccines, large vaccine and pharmaceutical companies, next-generation and regional developers, and delivery technology providers. Pfizer and BioNTech through Comirnaty and Moderna together accounted for an estimated 98.5% of the market in 2025. Key companies profiled in the report include Moderna, Inc., Pfizer Inc., BioNTech SE, CureVac, Merck & Co., Inc., Sanofi S.A., GSK plc, CSL Seqirus, Arcturus Therapeutics Holdings Inc., Daiichi Sankyo Company, Limited, Meiji Seika Pharma Co., Ltd., CSPC Pharmaceutical Group Limited, Walvax Biotechnology Co., Ltd., Gennova Biopharmaceuticals Ltd., Acuitas Therapeutics Inc., and Arbutus Biopharma Corporation.

How This Report Helps

Provides accurate market size estimates and long-term forecasts for the global mRNA vaccines market.

Evaluates the impact of mRNA platform adaptability, respiratory vaccine expansion, cancer vaccine development, public procurement, and regional manufacturing on market growth.

Identifies high-growth opportunities across vaccine types, technologies, indications, age groups, distribution channels, and geographic regions.

Analyzes emerging trends in self-amplifying mRNA, circular RNA, individualized neoantigen vaccines, combination respiratory vaccines, thermostable formulations, and lower-dose products.

Assesses the influence of COVID-19 demand contraction, vaccine hesitancy, safety perceptions, manufacturing overcapacity, intellectual property, reimbursement, and national recommendations on adoption.

Benchmarks leading companies based on clinical portfolios, technology platforms, manufacturing capabilities, regulatory progress, intellectual property, partnerships, and competitive positioning.

Supports product development, clinical planning, manufacturing strategy, investment decisions, partnership evaluation, market entry, procurement planning, and business expansion.

Delivers actionable market intelligence for vaccine manufacturers, pharmaceutical and biotechnology companies, governments, public health organizations, healthcare providers, oncology centers, investors, distributors, and research institutions.

Key Questions Answered

What is the current size of the global mRNA vaccines market, and how is it expected to evolve through 2036?

Which technological, clinical, regulatory, manufacturing, and economic factors are driving market growth?

What are the major drivers, restraints, opportunities, and challenges influencing industry development?

Which vaccine type, technology, indication, age-group, distribution-channel, and regional segments are expected to experience the strongest growth?

Why are Prophylactic Vaccines expected to account for the entire market in 2026, and why are Therapeutic Vaccines projected to grow fastest?

How will self-amplifying mRNA, circular RNA, lower-dose formulations, and improved storage stability influence market development?

How are oncology vaccines, individualized neoantigen design, and combination respiratory vaccines changing the commercial outlook?

Why is COVID-19 expected to decline while oncology and combination respiratory vaccines become major growth opportunities?

Which geographic markets present the most attractive business opportunities for mRNA vaccine companies?

How are regional manufacturing, technology-transfer partnerships, public procurement, and changing national recommendations affecting competition?

Who are the leading companies operating in the market, and what competitive strategies are they adopting?

What recent product approvals, clinical milestones, acquisitions, partnerships, intellectual property settlements, and technological innovations are shaping the competitive landscape?

How can stakeholders leverage market intelligence from this report to support investment decisions, product development, manufacturing planning, competitive benchmarking, and long-term business strategy?

Show more
Product Code: MRHC - 1042208

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Ecosystem
  • 1.3. Currency and Limitations
    • 1.3.1. Currency
    • 1.3.2. Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Data Collection & Validation Process
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research & Validation
      • 2.2.2.1. Primary Interviews with Industry Experts
      • 2.2.2.2. Country-/Region-Level Analysis
  • 2.3. Market Estimation
    • 2.3.1. Bottom-Up Approach (Product-Level Sales from Company Disclosures)
    • 2.3.2. Top-Down Approach (Vaccinated Population x Uptake x Price, by Indication and Country)
    • 2.3.3. Forecast Methodology (Probability-Weighted Pipeline Launches)
  • 2.4. Data Triangulation
  • 2.5. Assumptions

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Dynamics
    • 4.2.1. Drivers
      • 4.2.1.1. Speed and Adaptability of the mRNA Platform
      • 4.2.1.2. Expansion beyond COVID-19 into RSV and Next-Generation Formulations
      • 4.2.1.3. Advancement of Individualized mRNA Cancer Vaccines
      • 4.2.1.4. International Partnerships and Regional Manufacturing
    • 4.2.2. Restraints
      • 4.2.2.1. Sharp Post-Pandemic Decline in COVID-19 Vaccine Demand
      • 4.2.2.2. Reversal of U.S. Funding and Narrower Recommendations
      • 4.2.2.3. Safety Perceptions and Vaccine Hesitancy
      • 4.2.2.4. Manufacturing Overcapacity and Inventory Losses
    • 4.2.3. Opportunities
      • 4.2.3.1. Individualized Neoantigen Cancer Vaccines
      • 4.2.3.2. Combination Respiratory Vaccines
      • 4.2.3.3. Self-Amplifying mRNA
    • 4.2.4. Challenges
      • 4.2.4.1. Intellectual Property Disputes
      • 4.2.4.2. Clinical Setbacks and Durability Questions
      • 4.2.4.3. Competition from Alternative Vaccine Platforms
      • 4.2.4.4. Fragmented National Recommendations and Reimbursement
  • 4.3. Key Trends
    • 4.3.1. Transition from a Pandemic to a Seasonal and Oncology Market
    • 4.3.2. Cost Restructuring and Consolidation
    • 4.3.3. Next-Generation Formulations with Improved Stability and Lower Doses
    • 4.3.4. Geographic Diversification and Onshore Manufacturing
  • 4.4. Market Evolution Analysis (Pandemic Peak to Seasonal Market, 2020-2026)
  • 4.5. Approved mRNA Vaccine Landscape
  • 4.6. Pipeline Analysis
    • 4.6.1. Respiratory and Combination Vaccines
    • 4.6.2. Latent and Other Infectious Disease Vaccines
    • 4.6.3. Individualized and Shared-Antigen Cancer Vaccines
    • 4.6.4. Pandemic Preparedness Programs
  • 4.7. Technology Landscape
    • 4.7.1. Nucleoside Modification and Sequence Optimization
    • 4.7.2. Lipid Nanoparticle and Alternative Delivery Systems
    • 4.7.3. Self-Amplifying and Circular RNA
    • 4.7.4. Thermostability and Formulation Advances
  • 4.8. Intellectual Property and Litigation Landscape
  • 4.9. Policy, Regulatory, and Recommendations Landscape
    • 4.9.1. U.S. (FDA, ACIP, BARDA)
    • 4.9.2. Europe (EMA, National Immunization Programs)
    • 4.9.3. Asia-Pacific Regulatory Pathways
    • 4.9.4. WHO and Global Pandemic Preparedness Initiatives
  • 4.10. Manufacturing and Supply Chain Analysis
    • 4.10.1. Capacity Utilization and Onshore Manufacturing
    • 4.10.2. Raw Materials (Nucleotides, Enzymes, Lipids)
    • 4.10.3. Cold Chain and Distribution
  • 4.11. Pricing and Procurement Analysis
  • 4.12. Value Chain Analysis
  • 4.13. Porter's Five Forces Analysis

5. mRNA Vaccines Market, by Type

  • 5.1. Introduction
  • 5.2. Prophylactic Vaccines
  • 5.3. Therapeutic Vaccines

6. mRNA Vaccines Market, by Technology

  • 6.1. Introduction
  • 6.2. Conventional Non-Replicating mRNA
  • 6.3. Self-Amplifying mRNA
  • 6.4. Circular & Next-Generation RNA

7. mRNA Vaccines Market, by Indication

  • 7.1. Introduction
  • 7.2. COVID-19
  • 7.3. Respiratory Syncytial Virus (RSV)
  • 7.4. Influenza (Seasonal & Pandemic)
  • 7.5. Combination Respiratory Vaccines
  • 7.6. CMV & Latent Viruses
  • 7.7. Oncology
    • 7.7.1. Individualized Neoantigen Vaccines
    • 7.7.2. Shared-Antigen Cancer Vaccines
  • 7.8. Other Infectious Diseases

8. mRNA Vaccines Market, by Age Group

  • 8.1. Introduction
  • 8.2. Adults Aged 65+ & High-Risk Adults
  • 8.3. Adults Aged 18-64
  • 8.4. Pediatric

9. mRNA Vaccines Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Pharmacies & Retail Clinics
  • 9.3. Hospitals & Clinics
  • 9.4. Government & Public Health Programs
  • 9.5. Oncology Centers

10. mRNA Vaccines Market, by Geography

  • 10.1. Introduction
  • 10.2. North America
    • 10.2.1. U.S.
    • 10.2.2. Canada
  • 10.3. Europe
    • 10.3.1. Germany
    • 10.3.2. U.K.
    • 10.3.3. France
    • 10.3.4. Italy
    • 10.3.5. Spain
    • 10.3.6. Rest of Europe
  • 10.4. Asia-Pacific
    • 10.4.1. Japan
    • 10.4.2. China
    • 10.4.3. Australia
    • 10.4.4. South Korea
    • 10.4.5. India
    • 10.4.6. Taiwan
    • 10.4.7. Rest of Asia-Pacific
  • 10.5. Latin America
    • 10.5.1. Brazil
    • 10.5.2. Mexico
    • 10.5.3. Argentina
    • 10.5.4. Rest of Latin America
  • 10.6. Middle East & Africa
    • 10.6.1. Saudi Arabia
    • 10.6.2. UAE
    • 10.6.3. Israel
    • 10.6.4. South Africa
    • 10.6.5. Rwanda
    • 10.6.6. Rest of Middle East & Africa

11. Competitive Landscape

  • 11.1. Overview
  • 11.2. Key Growth Strategies
  • 11.3. Competitive Benchmarking
  • 11.4. Competitive Dashboard
    • 11.4.1. Industry Leaders
    • 11.4.2. Market Differentiators
    • 11.4.3. Vanguards
    • 11.4.4. Emerging Companies
  • 11.5. Market Share/Rank Analysis, by Key Player (2025)
    • 11.5.1. Pfizer Inc. (U.S.) and BioNTech SE (Germany)
    • 11.5.2. Moderna, Inc. (U.S.)
    • 11.5.3. Meiji Seika Pharma Co., Ltd. (Japan)
    • 11.5.4. Daiichi Sankyo Company, Limited (Japan)

12. Company Profiles

  • 12.1. Moderna, Inc.
    • 12.1.1. Business Overview
    • 12.1.2. Financial Overview
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Developments
    • 12.1.5. SWOT Analysis
  • 12.2. Pfizer Inc.
    • 12.2.1. Business Overview
    • 12.2.2. Financial Overview
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Developments
    • 12.2.5. SWOT Analysis
  • 12.3. BioNTech SE
    • 12.3.1. Business Overview
    • 12.3.2. Financial Overview
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Developments
    • 12.3.5. SWOT Analysis
  • 12.4. CureVac (BioNTech)
    • 12.4.1. Business Overview
    • 12.4.2. Financial Overview
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Developments
    • 12.4.5. SWOT Analysis
  • 12.5. Merck & Co., Inc.
    • 12.5.1. Business Overview
    • 12.5.2. Financial Overview
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Developments
    • 12.5.5. SWOT Analysis
  • 12.6. Sanofi S.A.
    • 12.6.1. Business Overview
    • 12.6.2. Financial Overview
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Developments
    • 12.6.5. SWOT Analysis
  • 12.7. GSK plc
    • 12.7.1. Business Overview
    • 12.7.2. Financial Overview
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Developments
    • 12.7.5. SWOT Analysis
  • 12.8. CSL Seqirus (CSL Limited)
    • 12.8.1. Business Overview
    • 12.8.2. Financial Overview
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Developments
    • 12.8.5. SWOT Analysis
  • 12.9. Arcturus Therapeutics Holdings Inc.
    • 12.9.1. Business Overview
    • 12.9.2. Financial Overview
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Developments
    • 12.9.5. SWOT Analysis
  • 12.10. Daiichi Sankyo Company, Limited
    • 12.10.1. Business Overview
    • 12.10.2. Financial Overview
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Developments
    • 12.10.5. SWOT Analysis
  • 12.11. Meiji Seika Pharma Co., Ltd.
    • 12.11.1. Business Overview
    • 12.11.2. Financial Overview
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Developments
    • 12.11.5. SWOT Analysis
  • 12.12. CSPC Pharmaceutical Group Limited
    • 12.12.1. Business Overview
    • 12.12.2. Financial Overview
    • 12.12.3. Product Portfolio
    • 12.12.4. Strategic Developments
    • 12.12.5. SWOT Analysis
  • 12.13. Walvax Biotechnology Co., Ltd.
    • 12.13.1. Business Overview
    • 12.13.2. Financial Overview
    • 12.13.3. Product Portfolio
    • 12.13.4. Strategic Developments
    • 12.13.5. SWOT Analysis
  • 12.14. Gennova Biopharmaceuticals Ltd.
    • 12.14.1. Business Overview
    • 12.14.2. Financial Overview
    • 12.14.3. Product Portfolio
    • 12.14.4. Strategic Developments
    • 12.14.5. SWOT Analysis
  • 12.15. Acuitas Therapeutics Inc.
    • 12.15.1. Business Overview
    • 12.15.2. Financial Overview
    • 12.15.3. Product Portfolio
    • 12.15.4. Strategic Developments
    • 12.15.5. SWOT Analysis
  • 12.16. Arbutus Biopharma Corporation
    • 12.16.1. Business Overview
    • 12.16.2. Financial Overview
    • 12.16.3. Product Portfolio
    • 12.16.4. Strategic Developments
    • 12.16.5. SWOT Analysis

13. Appendix

  • 13.1. Available Customization
  • 13.2. Related Reports
Show more
Product Code: MRHC - 1042208

LIST OF TABLES

List of Tables

  • Table 1 Global mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 2 Global Prophylactic mRNA Vaccines Market, by Country/Region, 2024-2036 (USD Million)
  • Table 3 Global Therapeutic mRNA Vaccines Market, by Country/Region, 2024-2036 (USD Million)
  • Table 4 Global mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 5 Global Conventional Non-Replicating mRNA Vaccines Market, by Country/Region, 2024-2036 (USD Million)
  • Table 6 Global Self-Amplifying mRNA Vaccines Market, by Country/Region, 2024-2036 (USD Million)
  • Table 7 Global Circular & Next-Generation RNA Vaccines Market, by Country/Region, 2024-2036 (USD Million)
  • Table 8 Global mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 9 Global mRNA Vaccines Market for COVID-19, by Country/Region, 2024-2036 (USD Million)
  • Table 10 Global mRNA Vaccines Market for RSV, by Country/Region, 2024-2036 (USD Million)
  • Table 11 Global mRNA Vaccines Market for Influenza, by Country/Region, 2024-2036 (USD Million)
  • Table 12 Global mRNA Vaccines Market for Combination Respiratory Vaccines, by Country/Region, 2024-2036 (USD Million)
  • Table 13 Global mRNA Vaccines Market for CMV & Latent Viruses, by Country/Region, 2024-2036 (USD Million)
  • Table 14 Global mRNA Vaccines Market for Oncology, by Type, 2024-2036 (USD Million)
  • Table 15 Global mRNA Vaccines Market for Oncology, by Country/Region, 2024-2036 (USD Million)
  • Table 16 Global mRNA Vaccines Market for Other Infectious Diseases, by Country/Region, 2024-2036 (USD Million)
  • Table 17 Global mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 18 Global mRNA Vaccines Market for Adults Aged 65+ & High-Risk Adults, by Country/Region, 2024-2036 (USD Million)
  • Table 19 Global mRNA Vaccines Market for Adults Aged 18-64, by Country/Region, 2024-2036 (USD Million)
  • Table 20 Global mRNA Vaccines Market for Pediatric, by Country/Region, 2024-2036 (USD Million)
  • Table 21 Global mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 22 Global mRNA Vaccines Market for Pharmacies & Retail Clinics, by Country/Region, 2024-2036 (USD Million)
  • Table 23 Global mRNA Vaccines Market for Hospitals & Clinics, by Country/Region, 2024-2036 (USD Million)
  • Table 24 Global mRNA Vaccines Market for Government & Public Health Programs, by Country/Region, 2024-2036 (USD Million)
  • Table 25 Global mRNA Vaccines Market for Oncology Centers, by Country/Region, 2024-2036 (USD Million)
  • Table 26 Global mRNA Vaccines Market, by Region, 2024-2036 (USD Million)
  • Table 27 Global mRNA Vaccines Market, by Country/Region, 2024-2036 (USD Million)
  • Table 28 North America: mRNA Vaccines Market, by Country/Region, 2024-2036 (USD Million)
  • Table 29 North America: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 30 North America: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 31 North America: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 32 North America: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 33 North America: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 34 U.S.: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 35 U.S.: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 36 U.S.: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 37 U.S.: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 38 U.S.: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 39 Canada: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 40 Canada: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 41 Canada: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 42 Canada: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 43 Canada: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 44 Europe: mRNA Vaccines Market, by Country/Region, 2024-2036 (USD Million)
  • Table 45 Europe: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 46 Europe: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 47 Europe: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 48 Europe: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 49 Europe: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 50 Germany: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 51 Germany: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 52 Germany: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 53 Germany: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 54 Germany: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 55 U.K.: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 56 U.K.: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 57 U.K.: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 58 U.K.: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 59 U.K.: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 60 France: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 61 France: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 62 France: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 63 France: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 64 France: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 65 Italy: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 66 Italy: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 67 Italy: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 68 Italy: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 69 Italy: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 70 Spain: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 71 Spain: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 72 Spain: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 73 Spain: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 74 Spain: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 75 Rest of Europe: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 76 Rest of Europe: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 77 Rest of Europe: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 78 Rest of Europe: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 79 Rest of Europe: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 80 Asia-Pacific: mRNA Vaccines Market, by Country/Region, 2024-2036 (USD Million)
  • Table 81 Asia-Pacific: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 82 Asia-Pacific: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 83 Asia-Pacific: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 84 Asia-Pacific: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 85 Asia-Pacific: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 86 Japan: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 87 Japan: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 88 Japan: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 89 Japan: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 90 Japan: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 91 China: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 92 China: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 93 China: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 94 China: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 95 China: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 96 Australia: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 97 Australia: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 98 Australia: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 99 Australia: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 100 Australia: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 101 South Korea: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 102 South Korea: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 103 South Korea: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 104 South Korea: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 105 South Korea: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 106 India: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 107 India: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 108 India: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 109 India: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 110 India: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 111 Taiwan: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 112 Taiwan: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 113 Taiwan: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 114 Taiwan: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 115 Taiwan: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 116 Rest of Asia-Pacific: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 117 Rest of Asia-Pacific: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 118 Rest of Asia-Pacific: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 119 Rest of Asia-Pacific: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 120 Rest of Asia-Pacific: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 121 Latin America: mRNA Vaccines Market, by Country/Region, 2024-2036 (USD Million)
  • Table 122 Latin America: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 123 Latin America: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 124 Latin America: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 125 Latin America: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 126 Latin America: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 127 Brazil: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 128 Brazil: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 129 Brazil: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 130 Brazil: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 131 Brazil: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 132 Mexico: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 133 Mexico: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 134 Mexico: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 135 Mexico: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 136 Mexico: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 137 Argentina: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 138 Argentina: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 139 Argentina: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 140 Argentina: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 141 Argentina: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 142 Rest of Latin America: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 143 Rest of Latin America: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 144 Rest of Latin America: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 145 Rest of Latin America: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 146 Rest of Latin America: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 147 Middle East & Africa: mRNA Vaccines Market, by Country/Region, 2024-2036 (USD Million)
  • Table 148 Middle East & Africa: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 149 Middle East & Africa: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 150 Middle East & Africa: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 151 Middle East & Africa: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 152 Middle East & Africa: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 153 Saudi Arabia: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 154 Saudi Arabia: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 155 Saudi Arabia: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 156 Saudi Arabia: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 157 Saudi Arabia: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 158 UAE: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 159 UAE: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 160 UAE: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 161 UAE: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 162 UAE: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 163 Israel: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 164 Israel: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 165 Israel: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 166 Israel: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 167 Israel: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 168 South Africa: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 169 South Africa: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 170 South Africa: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 171 South Africa: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 172 South Africa: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 173 Rwanda: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 174 Rwanda: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 175 Rwanda: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 176 Rwanda: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 177 Rwanda: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 178 Rest of Middle East & Africa: mRNA Vaccines Market, by Type, 2024-2036 (USD Million)
  • Table 179 Rest of Middle East & Africa: mRNA Vaccines Market, by Technology, 2024-2036 (USD Million)
  • Table 180 Rest of Middle East & Africa: mRNA Vaccines Market, by Indication, 2024-2036 (USD Million)
  • Table 181 Rest of Middle East & Africa: mRNA Vaccines Market, by Age Group, 2024-2036 (USD Million)
  • Table 182 Rest of Middle East & Africa: mRNA Vaccines Market, by Distribution Channel, 2024-2036 (USD Million)
  • Table 183 Recent Developments, by Company (2023-2026)
  • Table 184 mRNA Vaccines Market: Competitive Benchmarking, by Technology
  • Table 185 mRNA Vaccines Market: Competitive Benchmarking, by Indication
  • Table 186 mRNA Vaccines Market: Competitive Benchmarking, by Region
  • Table 187 Moderna, Inc.: mRNA Vaccine Product Portfolio
  • Table 188 Moderna, Inc.: Strategic Developments (2023-2026)
  • Table 189 Pfizer Inc.: mRNA Vaccine Product Portfolio
  • Table 190 Pfizer Inc.: Strategic Developments (2023-2026)
  • Table 191 BioNTech SE: mRNA Vaccine Product Portfolio
  • Table 192 BioNTech SE: Strategic Developments (2023-2026)
  • Table 193 CureVac (BioNTech): mRNA Vaccine Product Portfolio
  • Table 194 CureVac (BioNTech): Strategic Developments (2023-2026)
  • Table 195 Merck & Co., Inc.: mRNA Vaccine and Related Product Portfolio
  • Table 196 Merck & Co., Inc.: Strategic Developments (2023-2026)
  • Table 197 Sanofi S.A.: mRNA Vaccine and Related Product Portfolio
  • Table 198 Sanofi S.A.: Strategic Developments (2023-2026)
  • Table 199 GSK plc: mRNA Vaccine and Related Product Portfolio
  • Table 200 GSK plc: Strategic Developments (2023-2026)
  • Table 201 CSL Seqirus (CSL Limited): mRNA Vaccine and Related Product Portfolio
  • Table 202 CSL Seqirus (CSL Limited): Strategic Developments (2023-2026)
  • Table 203 Arcturus Therapeutics Holdings Inc.: mRNA Vaccine Product Portfolio
  • Table 204 Arcturus Therapeutics Holdings Inc.: Strategic Developments (2023-2026)
  • Table 205 Daiichi Sankyo Company, Limited: mRNA Vaccine and Related Product Portfolio
  • Table 206 Daiichi Sankyo Company, Limited: Strategic Developments (2023-2026)
  • Table 207 Meiji Seika Pharma Co., Ltd.: mRNA Vaccine and Related Product Portfolio
  • Table 208 Meiji Seika Pharma Co., Ltd.: Strategic Developments (2023-2026)
  • Table 209 CSPC Pharmaceutical Group Limited: mRNA Vaccine Product Portfolio
  • Table 210 CSPC Pharmaceutical Group Limited: Strategic Developments (2023-2026)
  • Table 211 Walvax Biotechnology Co., Ltd.: mRNA Vaccine and Related Product Portfolio
  • Table 212 Walvax Biotechnology Co., Ltd.: Strategic Developments (2022-2026)
  • Table 213 Gennova Biopharmaceuticals Ltd.: mRNA Vaccine and Related Product Portfolio
  • Table 214 Gennova Biopharmaceuticals Ltd.: Strategic Developments (2023-2026)
  • Table 215 Acuitas Therapeutics Inc.: Delivery Technology and Partner Portfolio
  • Table 216 Acuitas Therapeutics Inc.: Strategic Developments (2023-2026)
  • Table 217 Arbutus Biopharma Corporation: Delivery Technology and Product Portfolio
  • Table 218 Arbutus Biopharma Corporation: Strategic Developments (2023-2026)

LIST OF FIGURES

List of Figures

  • Figure 1 mRNA Vaccines Market Ecosystem
  • Figure 2 Currency Conversion Rates Used in the Study (Annual Average Exchange Rates, 2024-2025)
  • Figure 3 Key Stakeholders in the mRNA Vaccines Market
  • Figure 4 Research Process
  • Figure 5 Secondary Sources Referenced for This Study
  • Figure 6 Primary Research Techniques
  • Figure 7 Key Executives Interviewed
  • Figure 8 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
  • Figure 9 Market Sizing and Growth Forecast Approach
  • Figure 10 Data Triangulation
  • Figure 11 Global mRNA Vaccines Market, by Type, 2026 vs. 2036 (USD Million)
  • Figure 12 Global mRNA Vaccines Market, by Technology, 2026 vs. 2036 (USD Million)
  • Figure 13 Global mRNA Vaccines Market, by Indication, 2026 vs. 2036 (USD Million)
  • Figure 14 Global mRNA Vaccines Market, by Age Group, 2026 vs. 2036 (USD Million)
  • Figure 15 Global mRNA Vaccines Market, by Distribution Channel, 2026 vs. 2036 (USD Million)
  • Figure 16 Global mRNA Vaccines Market, by Geography, 2026 vs. 2036 (USD Million)
  • Figure 17 Impact Analysis of Market Dynamics
  • Figure 18 Evolution of the mRNA Vaccines Market, 2020-2026
  • Figure 19 Approved and Authorized mRNA Vaccines, by Indication, Developer, and Key Markets (As of September 2026)
  • Figure 20 mRNA Vaccine Pipeline, by Indication and Development Stage (As of September 2026)
  • Figure 21 mRNA Vaccine Technology Landscape
  • Figure 22 Key Intellectual Property Disputes and Settlements in mRNA Vaccines
  • Figure 23 Regulatory and Recommendations Framework for mRNA Vaccines
  • Figure 24 mRNA Vaccine Manufacturing and Supply Chain
  • Figure 25 Pricing and Procurement Models for mRNA Vaccines
  • Figure 26 Value Chain Analysis: mRNA Vaccines Market
  • Figure 27 Porter's Five Forces Analysis: mRNA Vaccines Market
  • Figure 28 Global mRNA Vaccines Market, by Type, 2026 vs. 2036 (USD Million)
  • Figure 29 Global mRNA Vaccines Market, by Technology, 2026 vs. 2036 (USD Million)
  • Figure 30 Global mRNA Vaccines Market, by Indication, 2026 vs. 2036 (USD Million)
  • Figure 31 Global mRNA Vaccines Market, by Age Group, 2026 vs. 2036 (USD Million)
  • Figure 32 Global mRNA Vaccines Market, by Distribution Channel, 2026 vs. 2036 (USD Million)
  • Figure 33 Global mRNA Vaccines Market: Top 15 Countries/Sub-Regions, 2026 vs. 2036 (USD Million)
  • Figure 34 North America: mRNA Vaccines Market Snapshot, 2026-2036 (USD Million)
  • Figure 35 Europe: mRNA Vaccines Market Snapshot, 2026-2036 (USD Million)
  • Figure 36 Asia-Pacific: mRNA Vaccines Market Snapshot, 2026-2036 (USD Million)
  • Figure 37 Latin America: mRNA Vaccines Market Snapshot, 2026-2036 (USD Million)
  • Figure 38 Middle East & Africa: mRNA Vaccines Market Snapshot, 2026-2036 (USD Million)
  • Figure 39 Key Growth Strategies Adopted by Leading Market Players (2023-2026)
  • Figure 40 Competitive Dashboard: mRNA Vaccines Market
  • Figure 41 Global mRNA Vaccines Market Share/Rank Analysis, by Key Players (2025)
  • Figure 42 Moderna, Inc.: Financial Snapshot (2025)
  • Figure 43 Moderna, Inc.: SWOT Analysis
  • Figure 44 Pfizer Inc.: Financial Snapshot (2025)
  • Figure 45 Pfizer Inc.: SWOT Analysis
  • Figure 46 BioNTech SE: Financial Snapshot (2025)
  • Figure 47 BioNTech SE: SWOT Analysis
  • Figure 48 CureVac: Financial Snapshot (2023-9M 2025)
  • Figure 49 CureVac (BioNTech): SWOT Analysis
  • Figure 50 Merck & Co., Inc.: Financial Snapshot (2025)
  • Figure 51 Merck & Co., Inc.: SWOT Analysis
  • Figure 52 Sanofi S.A.: Financial Snapshot (2025)
  • Figure 53 Sanofi S.A.: SWOT Analysis
  • Figure 54 GSK plc: Financial Snapshot (2025)
  • Figure 55 GSK plc: SWOT Analysis
  • Figure 56 CSL Limited: Financial Snapshot (FY2026)
  • Figure 57 CSL Seqirus (CSL Limited): SWOT Analysis
  • Figure 58 Arcturus Therapeutics Holdings Inc.: Financial Snapshot (2025)
  • Figure 59 Arcturus Therapeutics Holdings Inc.: SWOT Analysis
  • Figure 60 Daiichi Sankyo Company, Limited: Financial Snapshot (FY2025)
  • Figure 61 Daiichi Sankyo Company, Limited: SWOT Analysis
  • Figure 62 Meiji Holdings Co., Ltd.: Financial Snapshot (FY2025)
  • Figure 63 Meiji Seika Pharma Co., Ltd.: SWOT Analysis
  • Figure 64 CSPC Pharmaceutical Group Limited: Financial Snapshot (2025)
  • Figure 65 CSPC Pharmaceutical Group Limited: SWOT Analysis
  • Figure 66 Walvax Biotechnology Co., Ltd.: Financial Snapshot (2025)
  • Figure 67 Walvax Biotechnology Co., Ltd.: SWOT Analysis
  • Figure 68 Emcure Pharmaceuticals Ltd. (Parent of Gennova): Financial Snapshot (FY2025-26)
  • Figure 69 Gennova Biopharmaceuticals Ltd.: SWOT Analysis
  • Figure 70 Acuitas Therapeutics Inc.: SWOT Analysis
  • Figure 71 Arbutus Biopharma Corporation: Financial Snapshot (2025)
  • Figure 72 Arbutus Biopharma Corporation: SWOT Analysis
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!